admin The Indian vaccine already been put to use in India, Brazil and a number of other countries has conducted the third phase of its clinical trials and reported efficacy of 81%. Not only this, Bharat Biotech also claims that the trail also studied the effect of the vaccine on the new Brazilian variant and it was found to nullify it, that is work against it effectively.
The vaccine known as Covaxin is a two-dose vaccine that has been given to a number of people who have responded well. It is important to note that these results are also the interim and not the final efficacy rates.
The trials are still underway to scrutinise any form of result that might be there and within a span of a few days, we can expect the final efficacy rates of the vaccine. With a number of vaccine producers all around the world, more and more vaccines are emerging and proving to be effective.
With the phase 3 clinical trail reports, one can expect the vaccine to be allowed in a number of nations that were till date a little apprehensive about the same given that the complete trials had yet not been conducted.
The study was conducted on 25,00 people out of which half were given the vaccination while the other half received a placebo. The fact that it is effective against the new variant also proves to be a major advantage.
A number of vaccines that are being given to the people have not been found to be effective in particular against the Brazilian variant.
There were a few safety concerns raised by the people but the company has clarified that the vaccinations are safe for use and that no safety concerns were there during the trials.
The production has been ramped up to administer as many people as possible. All around the world, different vaccination programmes are being followed to inoculate the population. Recently, the United States also approved a single dose vaccine Johnson and Johnson to be administered to the people.
Magazine 
